EML4 and non-small cell lung carcinoma: According to our findings, EML4-ALK V1, V3a and V3b harboring the F1174S mutation are sensitive, rather than resistant, to crizotinib highlighting the complexity of monitoring and understanding resistance mechanisms in the NSCLC tumor landscape.